9 Other operating income and expenses
|
millions of CHF |
|
2022 |
|
2021 |
|
|
Gain from sale of property, plant and equipment |
|
0.1 |
|
0.1 |
|
|
Other operating income |
|
0.7 |
|
0.3 |
|
|
Total other operating income |
|
0.8 |
|
0.3 |
|
|
|
|
|
|
|
|
|
Restructuring expenses |
|
–1.1 |
|
–0.3 |
|
|
Impairments on tangible and intangible assets |
|
–1.5 |
|
–0.9 |
|
|
Cost for mergers and acquisitions |
|
–0.5 |
|
– |
|
|
Loss from sale of property, plant and equipment |
|
–0.1 |
|
–0.0 |
|
|
Operating currency exchange losses, net |
|
–2.8 |
|
–1.8 |
|
|
Deconsolidation of medmix Poland: Loss on net assets derecognized and retained investment |
|
–15.4 |
|
– |
|
|
Impairments on exposure against medmix Poland |
|
–5.9 |
|
– |
|
|
Write-downs on inventory acquired from medmix Poland |
|
–2.6 |
|
– |
|
|
Total other operating expenses |
|
–30.1 |
|
–3.0 |
|
|
|
|
|
|
|
|
|
Total other operating income / (expenses), net |
|
–29.3 |
|
–2.7 |
|
Other operating income includes income from litigation cases, government grants and incentives, and recharges to third parties not qualifying as revenues from customers.
For 2022, the group recognized restructuring costs of CHF 1.2 million (2021: CHF 0.5 million), partly offset by released restructuring provisions of CHF 0.0 million (2021: CHF 0.2 million). The group further performed impairment tests on production machines and facilities leading to impairments of CHF 1.5 million (2021: CHF 0.9 million). For more details, refer to note 12 and note 13.
The functional allocation of the total restructuring expenses and impairments is as follows: cost of goods sold CHF –1.8 million (2021: CHF –0.3 million), selling and administrative expenses CHF –0.7 million (2021: CHF –0.2 million) and research and development expenses CHF –0.1 million (2021: CHF –0.7 million).
In 2022, the group deconsolidated medmix Poland as of April 2022. The loss on the net assets derecognized and retained investment amounted to CHF 15.4 million (2021: CHF 0.0 million). Amounts owed to and from medmix Poland before losing control have been reclassified from intercompany receivables, loans and payables to third party receivables, loans and payables in the total net assets amount of CHF 11.8 million. The group further recognized impairments on the net exposure against medmix Poland in the amount of CHF 5.9 million (2021: CHF 0.0 million). For more details, reference is made to note 15.
The functional allocation of the impairments is as follows: Selling and administrative expenses CHF –1.1 million (2021: CHF 0.0 million), other financial income and expenses CHF –4.8 million (2021: CHF 0.0 million)
In 2022, after the deconsolidation of medmix Poland, the group acquired inventory from medmix Poland in the amount of CHF 6.2 million and was subsequently writing down the inventory by CHF 2.6 million (2021: CHF 0.0 million) to the net realizable value.